Evogliptin® (EVO), a novel DPP-4 inhibitor, was developed by Dong-A, Republic of Korea, and approved as an oral antihyperglycemic drug for the treatment of T2DM by the Ministry of Food and Drug Safety of Korea in 2015. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.